About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« Winter Storm Jonas Forces USPTO Closure on Monday and Tuesday | Main | CRISPR Interference Declared »

January 27, 2016


"The Representatives also take the NIH to task for declining to exercise march-in rights in the past while suggesting that controlling drug costs is a legislative duty."


With all due respect, I take these Representatives to task for making yet another IMPROPER request to the NIH to exert "march-in-rights" under Bayh-Dole as a means of drug price control. As the co-author of this legislation and others have correctly stated, these "march-in-rights" provisions were never intended to be exercised in this manner. And if "march-in-rights" are ever exercised for the purpose of drug price control, you might as well say good bye to any drug development involving federal-funding ever being commercialized.

The comments to this entry are closed.

February 2024

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29